Filing Analysis
Brainstorm Cell Therapeutics Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2026. The filing serves as a formal announcement of the company's recent operational and financial performance.
📋 Key Facts
- Report date: August 14, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes Exhibit 99.1 containing the full press release of financial results.
- Company is listed on the OTCQB Venture Market (Ticker: BCLI).
Brainstorm Cell Therapeutics announced a major leadership reshuffle involving the resignation of its Chairman (Jacob Frenkel, Ph.D.) and Chief Medical Officer (Ibrahim B. Dagher, MD), both of whom are transitioning to advisory/consulting roles. Simultaneously, Peter Pitts has been appointed as Executive Chairman and Chief Strategic Regulatory Officer.
🚩 Red Flags
- Multiple high-level departures (Chairman and CMO) in a single week.
- Significant equity acceleration and new RSU grants for departing/transitioning executives, which may indicate attempts to retain knowledge during instability or mitigate the impact of sudden exits.
- Potential leadership vacuum in clinical operations given the departure of the Chief Medical Officer.
📋 Key Facts
- Jacob Frenkel, Ph.D. resigned as Chairman and Director on July 24, 2026; transitioning to a consulting role.
- Ibrahim B. Dagher, MD, EVP and CMO, resigned effective July 26, 2026; transitioning to a one-year consulting role.
- Peter Pitts appointed Executive Chairman and Chief Strategic Regulatory Officer on July 24, 2026.
- Peter Pitts granted 900,000 stock options with a vesting schedule starting July 2027.
- Dr. Frenkel received an additional award of 100,000 RSUs as part of his consulting agreement.
- The company accelerated the vesting of Dr. Frenkel's outstanding equity upon his resignation.
Brainstorm Cell Therapeutics entered into a securities purchase agreement with Labrys Fund II, L.P., involving the issuance of a $143,750 promissory note. The note features a 25% conversion discount and is structured with monthly payments leading up to a maturity date in November 2026.
🚩 Red Flags
- Death spiral feature: The 25% conversion discount to the lowest trading price over 20 days is highly dilutive to existing shareholders.
- Debt obligation: The company has committed to monthly cash repayments starting in May 2026, which may strain liquidity for a micro-cap biotech.
- Small transaction size relative to typical operations suggests potential urgent need for bridge financing.
📋 Key Facts
- Entered into Securities Purchase Agreement with Labrys Fund II, L.P. on November 10, 2025.
- Issued a promissory note for $143,750 principal amount (includes $18,750 original issue discount).
- Received net funds of $121,500 after deducting $3,500 in legal fees.
- Note includes a 25% conversion discount to the lowest trading price over the prior 20 trading days.
- Conversion shares are subject to a 4.99% beneficial ownership limitation.
- Repayment schedule consists of six monthly payments of $22,589 starting May 11, 2026, through October 9, 2026.
- Maturity date is November 10, 2026.
Brainstorm Cell Therapeutics entered into a securities purchase agreement with Vanquish Funding Group Inc. on October 31, 2025, involving the issuance of a $182,400 promissory note. The financing includes a significant conversion discount and potential for additional tranches totaling up to $2 million.
🚩 Red Flags
- High-interest debt (12% base, 22% default) characteristic of distressed micro-cap financing.
- Significant conversion discount (35%) which is highly dilutive to existing shareholders.
- Potential for significant dilution via the $2 million aggregate financing option.
- Structured repayment schedule starting in April 2026 suggests immediate liquidity pressure.
📋 Key Facts
- Entered into Securities Purchase Agreement with Vanquish Funding Group Inc. on October 31, 2025.
- Issued a promissory note for $182,400 principal amount (includes $22,400 original issue discount).
- Net funds received: $155,000 after legal and due diligence fees of $5,000.
- Note bears 12% interest, increasing to 22% upon default.
- Conversion feature allows conversion at a 35% discount to the lowest trading price over the prior 10 trading days.
- Maturity date is August 30, 2026, with structured payments starting April 30, 2026.
- Agreement includes an option for Vanquish to provide up to $2 million in additional financing tranches over the next 12 months.
Brainstorm Cell Therapeutics Inc. filed an 8-K to furnish its quarterly financial results for the period ending June 30, 2025.
📋 Key Facts
- Report date: August 14, 2025
- Reporting Period: Quarter ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) containing the financial results.
- Company is listed on the OTCQB Venture Market under ticker BCLI.
Brainstorm Cell Therapeutics Inc. has been notified by Nasdaq that its common stock will be delisted from the Nasdaq Capital Market effective July 18, 2025, due to noncompliance with Listing Rule 5550(b)(1). The company plans to transition trading to the OTCQB market tier under the same symbol, BCLI.
🚩 Red Flags
- Delisting from a major exchange (Nasdaq) due to noncompliance with listing rules.
- Transition to OTC markets typically results in significantly lower liquidity and higher volatility.
- Non-compliance with Nasdaq Listing Rule 5550(b)(1) often relates to minimum bid price or shareholder equity requirements.
📋 Key Facts
- Nasdaq notified the company of delisting on July 16, 2025.
- Trading suspension on Nasdaq is effective at the open of trading on July 18, 2025.
- The company has been approved to quote its stock on the OTCQB market tier.
- Trading on OTCQB is expected to commence on or around July 18, 2025, under symbol BCLI.
Brainstorm Cell Therapeutics Inc. held its Annual Meeting of Stockholders on June 25, 2025, where shareholders approved several key proposals including the election of seven directors and amendments to stock incentive plans.
🚩 Red Flags
- Significant increase in share pool (from ~906k to ~2.9M shares) suggests potential future dilution for existing shareholders.
- Approval of Nasdaq Rule 5635(d) exemption indicates the company is utilizing warrants that could result in significant equity issuance.
📋 Key Facts
- Stockholders approved Amendment No. 5 to the 2014 Stock Incentive Plan and 2014 Global Share Option Plan on June 25, 2025.
- The amendment increases the share pool available for issuance by 2,000,000 shares, bringing the total pool to 2,906,666 shares.
- Seven directors were elected: Dr. Irit Arbel, Dr. Menghisteab Bairu, Dr. Jacob Frenkel, Nir Naor, Dr. Anthony Polverino, Uri Yablonka, and Dr. Stacy Lindborg.
- Shareholders ratified the appointment of Brightman Almagor Zohar & Co. (Deloitte Global Network) as independent auditors for fiscal year 2025.
- Stockholders approved a proposal regarding Nasdaq Listing Rule 5635(d) to allow issuance of shares upon exercise of warrants exceeding 20% of outstanding common stock.
Brainstorm Cell Therapeutics Inc. issued a press release regarding new survival data from ten participants in its Expanded Access Program for NurOwn® in treating amyotrophic lateral sclerosis (ALS). This is an informational update regarding clinical program progress.
📋 Key Facts
- Announced new survival data from 10 participants in the NurOwn® Expanded Access Program.
- The data pertains to patients with amyotrophic lateral sclerosis (ALS).
- Filing date: June 16, 2025.
Brainstorm Cell Therapeutics Inc. announced that it has received FDA clearance to initiate a Phase 3b clinical trial for its NurOwn® product, targeting the treatment of amyotrophic lateral sclerosis (ALS). This represents a significant regulatory milestone in the company's clinical development pipeline.
📋 Key Facts
- FDA clearance received on May 19, 2025, to initiate Phase 3b clinical trial.
- Product: NurOwn® (autologous MSC-NTF cells).
- Indication: Treatment of amyotrophic lateral sclerosis (ALS).
Brainstorm Cell Therapeutics Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: May 15, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results.
- Company is listed on the NASDAQ Capital Market under ticker BCLI.
Brainstorm Cell Therapeutics Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings and announced the date for its 2025 Annual Meeting of Stockholders.
🚩 Red Flags
- Reduction of quorum requirement can make it easier for a minority of shareholders to pass certain resolutions or hold meetings, which may be viewed as a governance shift.
📋 Key Facts
- Bylaws Amendment: Quorum requirement reduced from a majority in interest of all outstanding shares entitled to vote to one-third (1/3) in interest.
- 2025 Annual Meeting Date: Scheduled for Wednesday, June 25, 2025, at 10:00 a.m. ET.
- Meeting Format: The annual meeting will be held virtually.
- Record Date: May 7, 2025, is the record date for determining stockholders entitled to vote at the 2025 Annual Meeting.
Brainstorm Cell Therapeutics Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 31, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding results of operations and financial condition.
Brainstorm Cell Therapeutics entered into a warrant inducement agreement on March 31, 2025, to encourage an institutional holder to exercise existing warrants. In exchange for exercising up to 1,381,383 shares, the holder will receive new warrants equal to 200% of the exercised amount at an exercise price of $1.19 per share.
🚩 Red Flags
- Significant dilution: The issuance of new warrants at 200% of the exercised shares represents substantial potential dilution for existing shareholders.
- Warrant Inducement: Using 'sweeteners' to induce warrant exercise often indicates a company is struggling to raise capital through traditional means or needs immediate liquidity.
- Reliance on unregistered sales: The transaction relies on Section 4(a)(2) exemptions, which can lead to future registration requirements and volatility.
📋 Key Facts
- Expected gross proceeds from warrant exercise: approximately $1.64 million.
- New Warrants cover up to 2,762,766 shares (200% of the exercised amount).
- Exercise price for New Warrants is set at $1.19 per share.
- Transaction requires stockholder approval; a special or annual meeting will be called within 90 days.
- Maxim Group, LLC acting as agent with a 6.0% cash fee plus $12,500 in legal/out-of-pocket expenses.
- Proceeds are intended for working capital and general corporate purposes.
Brainstorm Cell Therapeutics Inc. has received an extension from the Nasdaq Hearings Panel to regain compliance with listing requirements through June 30, 2025. The company is attempting to satisfy a $2.5 million minimum stockholders' equity requirement in lieu of the standard $35 million Market Value of Listed Securities (MVLS) requirement.
🚩 Red Flags
- Delisting risk: The company faces potential removal from Nasdaq if compliance is not met by June 30, 2025.
- Liquidity/Capital Risk: The company explicitly states it cannot assure success in raising the necessary capital to meet equity requirements.
- Regulatory Pressure: The extension is subject to specific conditions and progress monitoring by the Panel.
📋 Key Facts
- Nasdaq Hearings Panel granted an extension until June 30, 2025, to regain compliance with Nasdaq Listing Rule 5550.
- The company is currently non-compliant with the $35 million MVLS Requirement.
- The proposed plan involves meeting a $2.5 million minimum stockholders' equity requirement instead of the MVLS requirement.
- Compliance is contingent upon successful capital raising activities and making progress on the presented Plan.
Brainstorm Cell Therapeutics Inc. has filed an appeal to Nasdaq's Hearings Panel following a failure to regain compliance with the Minimum Viable Listing Standard (MVLS) requirement by January 14, 2025. The company has successfully stayed the delisting action pending a hearing scheduled for February 25, 2025.
🚩 Red Flags
- Imminent delisting threat from Nasdaq Capital Market.
- Failure to meet Minimum Viable Listing Standard (MVLS) requirements.
- High uncertainty regarding the outcome of the February 25 hearing.
📋 Key Facts
- Company failed to regain compliance with Nasdaq's MVLS Requirement by the January 14, 2025 deadline.
- The company submitted a formal hearing request to the Nasdaq Hearings Panel on January 21, 2025.
- A hearing is scheduled for February 25, 2025, to demonstrate ability to regain and sustain compliance.
- The delisting action is currently stayed pending the final written decision by the Panel.
Brainstorm Cell Therapeutics Inc. has received notice from Nasdaq that it failed to regain compliance with the Minimum Market Value of Listed Securities (MVLS) requirement by the January 14, 2025 deadline. The company faces delisting from the Nasdaq Capital Market on January 24, 2025, unless an appeal is filed.
🚩 Red Flags
- Failure to meet Nasdaq minimum market value requirements
- Imminent delisting from a major exchange (Nasdaq Capital Market)
- Potential transition to over-the-counter (OTC) markets which reduces liquidity and visibility
📋 Key Facts
- The Company failed to meet the MVLS Requirement (minimum $35 million) between June 2, 2024, and July 17, 2024.
- Nasdaq provided a compliance period that expired on January 14, 2025.
- A formal notice of failure to regain compliance was received on January 15, 2025.
- The Company must request an appeal by January 22, 2025, to stay the delisting process.
- Delisting is scheduled for the opening of business on January 24, 2025, if no appeal is filed.
Brainstorm Cell Therapeutics Inc. filed an 8-K to furnish its quarterly financial results for the period ending September 30, 2024 via a press release.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes Exhibit 99.1 containing the full text of the press release regarding financial results.
Brainstorm Cell Therapeutics Inc. has regained compliance with the Nasdaq $1.00 minimum bid price requirement following a 1-for-15 reverse stock split. The company's common stock will continue to trade on the Nasdaq Capital Market.
🚩 Red Flags
- History of non-compliance with Nasdaq minimum bid price requirements (dating back to Nov 2023).
- Execution of a reverse stock split, which is often viewed negatively by the market and can be a sign of distress.
- The company remains subject to continued compliance with all other Nasdaq listing requirements.
📋 Key Facts
- Nasdaq confirmed on October 29, 2024, that the company has regained compliance with the $1.00 minimum bid price requirement (Rule 5550(a)(2)).
- The company successfully met the requirement by closing above $1.00 for ten consecutive trading days as of October 15, 2024.
- A 1-for-15 reverse stock split was executed on September 30, 2024, to facilitate compliance.
- The company had previously been facing delisting threats since November 2023.
Brainstorm Cell Therapeutics Inc. (BCLI) executed a 1-for-15 reverse stock split effective September 30, 2024. The action was taken to increase the per-share bid price to comply with Nasdaq's Minimum Bid Price Requirement and avoid delisting.
🚩 Red Flags
- Reverse stock split (Red flag escalator)
- Implicit delisting risk: The filing explicitly states the move is to meet Nasdaq's Minimum Bid Price Requirement, indicating the stock was trading below $1.00.
📋 Key Facts
- Reverse stock split ratio: 1-for-15.
- Effective date of reverse split: September 30, 2024, at 11:59 p.m. ET.
- Trading on a split-adjusted basis commenced October 1, 2024.
- New CUSIP number for common stock: 10501E300.
- Authorized shares remain unchanged at 250 million.
- Fractional shares will be paid in cash based on the closing price of the last trading day prior to effectiveness.
Brainstorm Cell Therapeutics, Inc. released a company presentation on October 1, 2024, to provide updates to investors via its website and as an exhibit to this filing.
📋 Key Facts
- The Company released a new company presentation on October 1, 2024.
- The presentation is available in the investor relations section of the Company’s website.
- Information provided under Item 7.01 is furnished but not considered 'filed' for purposes of Section 18 liability.
Brainstorm Cell Therapeutics Inc. has approved a 1-for-15 reverse stock split to be effective on September 30, 2024. The move is intended to address the company's need to regain compliance with Nasdaq minimum bid price requirements.
🚩 Red Flags
- Reverse stock split (often used to avoid delisting due to low share price)
- Explicit mention of the need 'to regain compliance with the minimum bid price requirement'
- Risk factor regarding 'continued listing of the Common Stock on Nasdaq'
📋 Key Facts
- The Board of Directors approved a one-for-fifteen (1:15) reverse stock split on September 23, 2024.
- The split is expected to become effective on September 30, 2024, at 11:59 p.m. ET.
- Shares will begin trading on a split-adjusted basis under the same symbol 'BCLI' on October 1, 2024.
- Every 15 shares of common stock will be converted into one share; fractional shares will be paid out in cash based on the closing price prior to the effective time.
- The action follows stockholder approval from the Annual Meeting held on September 16, 2024.
Brainstorm Cell Therapeutics Inc. held its Annual Meeting of Stockholders where shareholders approved several significant structural changes, including a massive increase in authorized shares and authorization for the Board to execute a reverse stock split.
🚩 Red Flags
- Authorization of a reverse stock split (1-for-5 to 1-for-15) is a classic indicator of potential delisting pressure or efforts to boost share price.
- Significant increase in authorized shares (from 100M to 250M) suggests readiness for large-scale equity dilution.
📋 Key Facts
- Stockholders approved an amendment to increase authorized Common Stock from 100,000,000 to 250,000,000 shares.
- Stockholders approved authorization for the Board to implement a reverse stock split with a ratio between 1-for-5 and 1-for-15 at its discretion on or before September 16, 2025.
- The 2014 Stock Incentive Plan and 2014 Global Share Option Plan were amended to increase the share pool by 8,000,000 shares (totaling 13,600,000) and extend their terms by ten years.
- Ratification of Brightman Almagor Zohar & Co. as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
Brainstorm Cell Therapeutics Inc. filed an 8-K to furnish its quarterly financial results for the period ending June 30, 2024 via a press release.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial results pertain to the quarter ended June 30, 2024.
- Results were released on August 14, 2024.
Brainstorm Cell Therapeutics Inc. announced the scheduling of its 2024 Annual Meeting of Stockholders, to be held virtually on September 16, 2024. The filing provides updated deadlines for stockholder proposals and director nominations due to the meeting date differing from the previous year's anniversary.
📋 Key Facts
- 2024 Annual Meeting scheduled for Monday, September 16, 2024, at 10:00 a.m. ET.
- The meeting will be held virtually.
- Record date for stockholders entitled to vote is August 12, 2024.
- Deadline for stockholder proposals for inclusion in proxy materials (Rule 14a-8) is August 12, 2024.
- Deadline for director nominations under Rule 14a-19 is August 9, 2024.
Brainstorm Cell Therapeutics Inc. received a deficiency notice from Nasdaq because its Market Value of Listed Securities (MVLS) fell below the required $35 million threshold between June 2, 2024, and July 17, 2024. The company has until January 14, 2025, to regain compliance by maintaining an MVLS of at least $35 million for ten consecutive business days.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq listing rules (Rule 5550(b)(2)).
- Market capitalization has fallen below the required threshold, indicating significant loss in shareholder value or market confidence.
- Risk of delisting if compliance is not met by January 14, 2025.
📋 Key Facts
- Received MVLS Deficiency Notice from Nasdaq on July 18, 2024.
- MVLS was below the required $35 million minimum between June 2, 2024, and July 17, 2024.
- Compliance deadline (Compliance Date) is January 14, 2025.
- To regain compliance, MVLS must close at $35 million or more for a minimum of ten consecutive business days during the compliance period.
Brainstorm Cell Therapeutics Inc. entered into a Securities Purchase Agreement to raise approximately $4.0 million through the sale of common stock, pre-funded warrants, and unregistered warrants at a price of roughly $0.36 per share. The offering includes significant warrant coverage that will lead to substantial future dilution.
🚩 Red Flags
- Significant potential dilution: The issuance of over 16.6 million unregistered warrants represents a massive amount of future common stock relative to current market cap.
- Low share price: The offering price of $0.36 per share is characteristic of highly distressed micro-cap financing.
- Warrant Amendment: Existing warrants from July 2023 were amended as part of this deal, indicating restructuring of debt/equity obligations.
📋 Key Facts
- Gross proceeds from the offering are approximately $4.0 million before fees.
- Securities include 7,918,764 registered shares of common stock and 3,192,347 pre-funded warrants.
- Unregistered warrants were issued to purchase up to 16,666,667 shares of Common Stock.
- Warrants have an exercise price of $0.3912 per share and expire in five years.
- Maxim Group LLC is acting as the exclusive placement agent with a 6.0% cash fee.
- The company will file an S-3 registration statement to register the resale of shares underlying the warrants by December 26, 2024.
Brainstorm Cell Therapeutics announced on June 26, 2024, that it has reached alignment with the FDA regarding Chemistry, Manufacturing, and Controls (CMC) for its Phase 3b clinical trial of NurOwn®, an investigational therapy for ALS.
📋 Key Facts
- Reached alignment with the FDA on CMC aspects for the NurOwn® Phase 3b clinical trial.
- The therapeutic target is amyotrophic lateral sclerosis (ALS).
- Filing date: June 26, 2024.
Brainstorm Cell Therapeutics Inc. announced the appointment of Dr. Hartounian as Executive Vice President and Chief Operating Officer, effective June 24, 2024. The filing details his extensive background in biotechnology leadership and the specific terms of his employment agreement.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Dr. Hartounian appointed as EVP and COO, effective June 24, 2024.
- Base annual salary: $450,000.
- Equity compensation includes an option to purchase 60,000 shares of common stock and a one-time grant of 30,000 shares of restricted common stock.
- Option vesting schedule: 25% on the first anniversary; remaining 75% in equal quarterly installments over the following three years.
- Restricted Stock Grant vests in full on the first anniversary of the start date.
- Eligible for an annual cash bonus of up to 35% of base salary and a $10,000 signing bonus.
Brainstorm Cell Therapeutics Inc. has received a temporary exception from Nasdaq, extending its deadline to regain compliance with the $1.00 minimum bid price requirement until October 21, 2024. The company must implement a reverse stock split by October 7, 2024, if it fails to achieve compliance through other means by mid-August 2024.
🚩 Red Flags
- Delisting notice/non-compliance with minimum bid price requirement
- Likely upcoming reverse stock split to avoid delisting
- Ongoing struggle to maintain minimum market price
📋 Key Facts
- Nasdaq granted a temporary exception until October 21, 2024, following an expedited review process.
- The company must regain compliance with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- A reverse stock split is anticipated if compliance is not achieved by mid-August 2024 to meet the October 7, 2024 deadline.
- Failure to regain compliance by October 21, 2024, will result in delisting from the Nasdaq Capital Market.
Brainstorm Cell Therapeutics Inc. failed to regain compliance with Nasdaq's $1.00 minimum bid price requirement by the April 29, 2024 deadline. The company has filed an appeal to the Nasdaq Hearings Panel and is participating in an expedited review process to stay delisting.
🚩 Red Flags
- Failure to meet minimum bid price requirement (delisting risk)
- Potential for suspension of securities if appeal is unsuccessful
- Uncertainty regarding the Panel's acceptance of the company's compliance plan
📋 Key Facts
- The company failed to meet the Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)) by April 29, 2024.
- On May 2, 2024, the Company submitted a hearing request to the Nasdaq Hearings Panel to appeal the Staff's determination.
- The hearing request has stayed the suspension of securities and the filing of Form 25-NSE pending a final decision.
- The company intends to participate in an expedited review process with the Panel.
- Trading on Nasdaq under symbol 'BCLI' continues in the interim while the appeal is pending.
Brainstorm Cell Therapeutics announced the resignation of Co-CEO Dr. Stacy Lindborg, effective May 9, 2024, and her subsequent appointment to the Board of Directors. Additionally, Dr. Ibrahim B. Dagher has been promoted to Executive Vice President and Chief Medical Officer.
🚩 Red Flags
- Executive turnover (Co-CEO departure) can create leadership instability in micro-cap biotech firms.
- Cash outflow of $300,000 for a separation bonus in a potentially capital-constrained environment.
📋 Key Facts
- Dr. Stacy Lindborg is resigning as Co-CEO effective May 9, 2024; she will transition to a non-employee Director role on the same date.
- The company will pay Dr. Lindborg a $300,000 lump sum separation bonus by March 15, 2025.
- Dr. Lindborg's unvested equity awards (except for a specific March 11, 2024 RSA grant) will be forfeited upon her departure from the executive role.
- The March 11, 2024 RSA grant of 241,935 shares will continue to vest while she serves on the Board and features an acceleration clause upon a change of control.
- Dr. Ibrahim B. Dagher has been promoted from Chief Development Officer to Executive Vice President and Chief Medical Officer.
- The company stated Dr. Lindborg's resignation is not due to any disagreement with the Company or its Board.
Brainstorm Cell Therapeutics Inc. has regained compliance with the Nasdaq Minimum Market Value Requirement, resolving a delisting threat initiated in November 2023.
🚩 Red Flags
- Historical delisting risk (though currently resolved)
📋 Key Facts
- On April 10, 2024, Nasdaq notified the Company that it has regained compliance with the Minimum Market Value Requirement under Nasdaq Listing Rule 5550(b)(2).
- The deficiency was originally identified on November 6, 2023, due to market value falling below $35 million.
- The matter regarding the minimum market value requirement is now considered closed by Nasdaq.
Brainstorm Cell Therapeutics announced that the FDA has granted a Special Protocol Assessment (SPA) for the design of its Phase 3b clinical trial of NurOwn® in treating amyotrophic lateral sclerosis (ALS). This represents a significant regulatory milestone for the company's lead product candidate.
📋 Key Facts
- FDA issued written agreement under a Special Protocol Assessment (SPA) on April 9, 2024.
- The SPA pertains to the design of a Phase 3b trial for NurOwn® in amyotrophic lateral sclerosis (ALS).
- Company scheduled a conference call and webcast for April 9, 2024, to discuss the development.
Brainstorm Cell Therapeutics Inc. amended its existing at-the-market (ATM) equity offering program to remove Leerink Partners LLC as an agent.
🚩 Red Flags
- Reduction in number of agents for ATM offering may indicate a shift in brokerage relationships or strategic restructuring of capital raising efforts.
📋 Key Facts
- Amendment No. 1 to the Distribution Agreement was executed on April 2, 2024.
- The original agreement dated August 9, 2021, allows for the sale of common stock up to an aggregate offering price of $100.0 million.
- Leerink Partners LLC has ceased to be an agent under the Distribution Agreement.
- Raymond James & Associates, Inc. remains as an agent in the program.
Brainstorm Cell Therapeutics Inc. filed an 8-K to furnish its annual financial results for the fiscal year ended December 31, 2023 via a press release.
📋 Key Facts
- Report date: April 1, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the full text of the earnings press release.
- The company is listed on the NASDAQ Capital Market under ticker BCLI.